• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Lyra touts non-human trial of XTreo drug-eluting implant

September 10, 2021 By Sean Whooley

Lyra Therapeutics LYR-210
LYR-210 is an investigational product designed to provide six months of anti-inflammatory treatment from a single in-office administration
(Image from Lyra Therapeutics)

Lyra Therapeutics (NSDQ:LYRA) is touting preclinical data for its XTreo drug-eluting implant for dosing in local sinus tissues.

Watertown, Massachusetts-based Lyra’s preclinical results were published — “Drug Release and Pharmacokinetic Evaluation of Novel Implantable Mometasone Furoate Matrices in Rabbit Maxillary Sinuses” — were published online in the peer-review journal, American Journal of Rhinology & Allergy.

The pharmacokinetics and drug release study evaluated the release of mometasone furoate (MF), a potent anti-inflammatory corticosteroid formulated into Lyra’s proprietary XTreo matrix in a rabbit model, according to a news release. XTreo, comprised of a flexible mesh capable of taking a high payload of a drug, provides a consistent release of the therapeutic over time, with Lyra touting capabilities of six months of drug delivery.

Lyra said the results demonstrate that XTreo MF provides targeted, sustained and efficient dosing to local sinus tissues that is superior to intranasal corticosteroid sprays (INCS).

In the study, XTreo matrices self-expanded upon deployment to conform to the irregular geometry of the maxillary sinus cavities and provided a sustained release of MF in vitro and in vivo for two MF matrices of distinct release durations. Low levels of MF were detected in plasma, demonstrating XTreo’s ability to maximize the therapeutic effect to the immediately contacted tissues and potentially eliminate systemic side effects.

“The outcomes from this study supported Lyra’s advancement into clinical development for the first application of our novel XTreo platform, LYR-210 for the treatment of Chronic Rhinosinusitis (CRS), which is now poised to enter Phase 3 studies,” Lyra president & CEO Maria Palasis said in the release. “XTreo is a powerful drug delivery platform that can target a precise dose of a therapeutic agent consistently over an extended period of time, up to many months. These characteristics translate into multiple potential benefits, including increased efficacy, elimination of patient adherence issues, and avoidance of systemic side effects. We believe our proprietary platform technology can provide optimal treatment for CRS, as well as other chronic ear, nose and throat (ENT) diseases.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Otolaryngology Ear, Nose & Throat Tagged With: Lyra Therapeutics

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS